Payment overview · 2025
General Payments
$1,218.28
66 reported records · 17 companies
Healthcare provider profile · identity verified
Dustin K Devers, DO
Allopathic & Osteopathic Physicians|Family Medicine · PAINTSVILLE, KY · NPI 1699989640
Verified facts
What the public records show
CMS Open Payments records show Dustin K Devers, DO received $1,218.28 in general payments during 2025 across 66 reported records.
ABBVIE INC. accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 400 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $377.63 | 31.0% | 26 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $164.36 | 13.5% | 6 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $139.56 | 11.5% | 6 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $128.76 | 10.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.09 | 6.0% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $51.42 | 4.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$47.80 | 3.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.42 | 3.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.75 | 3.8% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $23.15 | 1.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.63 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.36 | 1.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.28 | 1.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.67 | 1.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.08 | 1.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.68 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.64 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,153.29 | 65 |
| Education | $64.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $268.86 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $131.13 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $116.21 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $108.77 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $108.77 | 12 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $83.85 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $82.98 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $64.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.63 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $51.42 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $47.80 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.42 | 2 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $44.91 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.03 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.84 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.84 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 400 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
400 | 52 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 772 | 163 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 743 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 577 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 508 | 129 |
| Gabapentin | Gabapentin | 485 | 85 |
| Eliquis | Apixaban | 400 | 52 |
| Lisinopril | Lisinopril | 380 | 81 |
| Sertraline Hcl | Sertraline Hcl | 363 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 92 |
| Buspirone Hcl | Buspirone Hcl | 334 | 53 |
| Furosemide | Furosemide | 333 | 70 |
| Mirtazapine | Mirtazapine | 327 | 60 |
| Omeprazole | Omeprazole | 324 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 310 | 60 |
| Quetiapine Fumarate | Quetiapine Fumarate | 308 | 40 |
| Trazodone Hcl | Trazodone Hcl | 277 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 243 | 52 |
| Potassium Chloride | Potassium Chloride | 239 | 47 |
| Montelukast Sodium | Montelukast Sodium | 233 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 57 |
| Carvedilol | Carvedilol | 224 | 46 |
| Famotidine | Famotidine | 218 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 214 | 46 |
| Losartan Potassium | Losartan Potassium | 201 | 55 |
| Donepezil Hcl | Donepezil Hcl | 199 | 38 |
| Tramadol Hcl | Tramadol Hcl | 194 | 35 |
| Spironolactone | Spironolactone | 183 | 44 |
| Diazepam | Diazepam | 181 | 47 |
| Pregabalin | Pregabalin | 181 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 173 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 154 | 28 |
| Memantine Hcl | Memantine Hcl | 141 | 20 |
| Meloxicam | Meloxicam | 140 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 37 |
| Simvastatin | Simvastatin | 126 | 26 |
| Divalproex Sodium | Divalproex Sodium | 125 | 18 |
| Finasteride | Finasteride | 122 | 30 |
| Allopurinol | Allopurinol | 121 | 25 |
| Alprazolam | Alprazolam | 117 | 15 |
| Clonazepam | Clonazepam | 117 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 34 |
| Bumetanide | Bumetanide | 115 | 20 |
| Lorazepam | Lorazepam | 112 | 33 |
| Dexamethasone | Dexamethasone | 111 | 86 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 25 |
| Temazepam | Temazepam | 109 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 108 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 106 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 25 |
| Ondansetron Odt | Ondansetron | 95 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 95 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 93 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 87 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 27 |
| Metformin Hcl | Metformin Hcl | 84 | 24 |
| Azithromycin | Azithromycin | 80 | 61 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | 17 |
| Levetiracetam | Levetiracetam | 77 | 11 |
| Constulose | Lactulose | 75 | 19 |
| Cefdinir | Cefdinir | 73 | 57 |
| Entresto | Sacubitril/Valsartan | 73 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 70 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 12 |
| Xarelto | Rivaroxaban | 69 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 21 |
| Torsemide | Torsemide | 68 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 15 |
| Ozempic | Semaglutide | 66 | 13 |
| Prednisone | Prednisone | 66 | 29 |
| Metformin Hcl Er | Metformin Hcl | 64 | 23 |
| Warfarin Sodium | Warfarin Sodium | 61 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 60 | 13 |
| Midodrine Hcl | Midodrine Hcl | 60 | 13 |
| Gemtesa | Vibegron | 58 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 15 |
| Fluconazole | Fluconazole | 54 | 33 |
| Promethazine Hcl | Promethazine Hcl | 54 | 15 |
| Glipizide | Glipizide | 52 | 14 |
| Ibuprofen | Ibuprofen | 52 | 14 |
| Valsartan | Valsartan | 52 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | 13 |
| Celecoxib | Celecoxib | 51 | 16 |
| Baclofen | Baclofen | 50 | suppressed |
| Nystatin | Nystatin | 50 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 13 |
| Linzess | Linaclotide | 49 | 11 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Estradiol | Estradiol | 48 | 15 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Cephalexin | Cephalexin | 47 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 11 |
| Synthroid | Levothyroxine Sodium | 46 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 29 |
| Methocarbamol | Methocarbamol | 42 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 26 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 19 |
| Atenolol | Atenolol | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 36 | suppressed |
| Vraylar | Cariprazine Hcl | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Myrbetriq | Mirabegron | 35 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 13 |
| Brilinta | Ticagrelor | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Roflumilast | Roflumilast | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 32 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Glyburide Micronized | Glyburide,micronized | 32 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 18 |
| Azelastine Hcl | Azelastine Hcl | 30 | 13 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 30 | 17 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Scopolamine | Scopolamine | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 20 |
| Jentadueto | Linagliptin/Metformin Hcl | 29 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 29 | 19 |
| Methimazole | Methimazole | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Sulfasalazine | Sulfasalazine | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Austedo | Deutetrabenazine | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Enulose | Lactulose | 27 | suppressed |
| Lubiprostone | Lubiprostone | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 11 |
| Sulindac | Sulindac | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | 12 |
| Morphine Sulfate | Morphine Sulfate | 22 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Tegretol Xr | Carbamazepine | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Lactulose | Lactulose | 19 | 15 |
| Sucralfate | Sucralfate | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | 13 |
| Nitroglycerin | Nitroglycerin | 15 | 12 |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Admelog | Insulin Lispro | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Pirfenidone | Pirfenidone | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,218.28 · 66 records | ABBVIE INC. | AIRSUPRA, Andembry, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, GEMTESA, Haegarda, INGREZZA, KISUNLA, MINIMED 780G, MOUNJARO, NURTEC ODT, Omnipod, PAXLOVID, QULIPTA, REXULTI, TZIELD, UBRELVY, UZEDY, VRAYLAR, Wegovy, XYWAV, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error